In January of 1992 Viral Response Systems, Inc. and Robert S. Krauser agreed to a consent decree with the FTC relating to the advertising and promotion of the Viralizer with ViraSpray, for the reief of Cold, Allergy, Sore Throat and Sinusitis Symptoms.
As one Washington based regulatory atorney put it: "When you sign a consent decree, you are basically agreeing not to do, what you never did."
Along these lines, Viral Response published the "VIRALIZER CHALLENGE", included in full page advertisements in the Chicago Tribune, USA Today and the New York Times, which listed the FTC prepared charges and offered a $50,000 reward to anybody who could come forward with an advertisement or publicity release prepared by Viral Response systems and/or Robert S. Krauser which contained material covered by the FTC charges. NOBODY CAME FORWARD TO CLAIM THE $50,000 REWARD, NOBODY MET THE CHALLENGE!
As Casewatch indicated the prohibited claims were:
destroy, disable, or help destroy or disable any virus responsible for the onset or continuance of colds;
prevent or help prevent the spread or transmission of colds;
provide or help provide permanent or long term relief from any allergy symptoms;
destroy, disable or help destroy or disable, any antibody that plays a part in the manesfestation of any allergic reaction; or
cure or help to cure colds...
Viralizer advertiswing was always limited to claims of the relief of cold, allergy, sore throat and sinusitis symptoms, CLAIMS WHICH WERE APPROVED IN WRITING BY THE FDA!
It was curious that the FTC brought the charges in the first place,
it was curious that they named Robert S. Krauser, in addition to the company in the complaint, even the FTC administrtive law judge thought this unusual, and
it was curious that Casewatchchose to put out their release on the Internet pertaining to the Viralizer and the FTC, in August of 2006, referring back ato the FTC press release of January 1992.
THE $50,000 VIRALIZER CHALLENGE IS STILL OPEN AND NOBODY, NOT EVEN ANYBODY RELATED TO EMPLOYEES OF THE FTC, HAS COME FORWARD TO CLAIM THE $50,000!
Viral response has sponsored double blind clinicals at the University of California San Diego Medical Center as well as the James M. Gamble Institute of Medical Research, Clinical Virology Division, among others, which demonstrate the safety and efficacy of the Viraizer, for the relief of cold symptoms. In fact, the Gamble study went beyond public Viralizer claims and additionally concluded, "LASTLY, EVIDENCE FROM THIS AND THE LAST STUDY SUGGESTS THAT VIRALIZER THERAPY IS INDEED ANTIVIRAL" (Please note that Viral Response Systems never made this claim.)